Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More

Exosome Diagnostics Places Its First Early Access Shahky System within a Top 15 Pharmaceutical Laboratory

Waltham, MA- January 8, 2018 - Exosome Diagnostics has announced the placement of the world’s first system for exosome specific protein analysis, the Shahky system, within a large pharmaceutical company. The companies have near term plans to develop targeted assays containing clinically relevant biomarkers of interest, utilizing the Shahky system. 
By targeting disease specific exosomes and removing non-relevant proteins, the Shahky system is a powerful tool for drug development and patient stratification. The system enables rapid development of definitive disease specific exosomal protein biomarker signatures from any biofluid, including blood, cerebrospinal fluid, plasma, serum, urine, saliva, and ascites fluid.
“Exosome Dx is thrilled to continue expanding upon its strong partnerships within Pharma by giving them access to the newest of ExoDx’s novel technologies” stated Mario Morken, Head of Business Development at Exosome Diagnostics. “By granting Pharma access to Shahky we aim to enable new discoveries and developments that will have therapeutic and/or diagnostic significance, building upon our foothold in the exoRNA and cfDNA space” Morken continued.

The commercial version of the Shahky, to be released in 2018 is on track to enable the following specs:

• Ten microliters of biofluid input
• Label free detection
• Four-minute run time
• High sensitivity and specificity (1000x more sensitive than Western Blots and 100X more sensitive than ELISA)
• Small desktop footprint (12” x 16” x 18”) - optimal for clinical laboratories
• Quantitative disease specific protein analysis

“The Shahky system will allow pharmaceutical companies and researchers to leverage the full breadth of the Exosome Diagnostics’ solution, from liquid biopsy-based nucleic acid biomarkers to liquid-biopsy based protein biomarkers,” stated John Boyce, President and CEO of Exosome Diagnostics. “Exosome’s mantra has been to let the science dictate both the analyte and the measurement technology to derive the most predictive diagnostics tests. With the Shahky system, the company has now realized that vision,” Boyce continued. 

Downlad a PDF of this press release

About Exosome Diagnostics

Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, and point of care instrument for protein capture and analysis, Shahky™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are diagnosed, treated and monitored. Visit to learn more.

Company / Media Contact

Dan Baughman
Exosome Diagnostics